UnitedHealth Group Incorporated – Consensus Indicates Potential 9.1% Upside

DirectorsTalk Interviews

UnitedHealth Group Incorporated with ticker code (UNH) have now 24 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 632 and 360 and has a mean target at 573.79. Given that the stocks previous close was at 525.86 this now indicates there is a potential upside of 9.1%. There is a 50 day moving average of 528.68 and the 200 day MA is 498.92. The market cap for the company is $493,424m. Visit the company website at: https://www.unitedhealthgroup.com

The potential market cap would be $538,397m based on the market concensus.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage and well-being services to individuals age 50 and older addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children’s health insurance and health care programs; health and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.

Share on:
Find more news, interviews, share price & company profile here for:

    Likewise granted approval for 20,000 sq ft expansion of Newport facility

    Likewise Group has received planning permission to extend its Newport warehouse by 20,000 sq ft, creating a 55,000 sq ft distribution hub. The development will be funded through internal cash flow.

    Cerillion secures £17.3m follow-on contracts with major European customer

    Cerillion has signed two agreements worth a combined £17.3 million with an existing European customer, following an £8 million services contract announced in May 2025.

    Avation reports US$110m revenue and strengthened balance sheet for FY25

    Avation expects revenue of around US$110 million for the year to 30 June 2025. The company has reduced outstanding bond debt to US$298 million through repurchases and improved its credit ratings with Moody’s and Fitch.

    JPMorgan European Discovery Trust reports strong performance uplift in latest factsheet

    JPMorgan European Discovery Trust reported a 5.37% share price rise in July 2025, outpacing NAV and its benchmark. Year-to-date, the share price is up 34.17%, supported by strong small-cap performance and effective stock selection.

    Golden Matrix reports record August revenue of $17.8m, up 18% year-on-year

    Golden Matrix posted record August revenues of $17.8m, up 18% from last year, with July revenues also rising 24% to $15.7m. Strong performance came from Meridianbet’s sports betting and RKings’ tournaments, positioning the group for record Q3 results.

    HUTCHMED to present new lung cancer and oncology data at WCLC and CSCO 2025

    HUTCHMED announced that updated data on savolitinib in NSCLC and other pipeline compounds will be presented at the World Conference on Lung Cancer in Barcelona and the CSCO Annual Meeting in China this September. Presentations include studies on savolitinib, surufatinib, fruquintinib and first-in-human results for HMPL-653.

      Search

      Search